Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study-Reference-Cited by-同舟云学术

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study

Published:2021-10-18 Issue:11 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Li Yinjuan¹,Qi Lu¹,Bai Haihong¹,Sun Chunyun²³⁴,Xu Shuping²,Wang Yu¹,Han Chunyu¹,Li Yan¹,Liu Long¹,Cheng Xiaoqiang¹,Liu Ju¹,Lei Chunpu¹,Tong Yuanxu¹,Sun Mingli¹,Yan Lixin²,Chen Weiqiu²,Liu Xisheng²,Liu Qing²,Xie Liangzhi²³⁴,Wang Xinghe¹^ORCID

Affiliation:

1. Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

2. Sinocelltech Ltd., Beijing, China

3. Beijing Engineering Research Center of Protein and Antibody, Beijing, China

4. Cell Culture Engineering Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Abstract

SCTA01 is a novel monoclonal antibody with promising prophylactic and therapeutic potential for COVID-19. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of SCTA01 in healthy adults.

Funder

Beijing Municipal Science and Technology Project

National Science and Technology Major Project

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01063-21

Reference32 articles.

1. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia

2. Survival of patients with lung cancer and diabetes mellitus